NKILA inhibits NF-κB signaling and suppresses tumor metastasis

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Long non-coding RNAs (lncRNAs) play critical roles in cancer.
• NKILA (nuclear transcription factor NF-κB interacting lncRNA) is a known tumor suppressor in breast and tongue cancers.
• The role of NKILA in esophageal squamous cell carcinoma (ESCC) is currently unknown.

Purpose of the Study:

• To investigate the clinical significance and biological functions of NKILA in ESCC.
• To elucidate the underlying molecular mechanisms of NKILA's action in ESCC.
• To evaluate NKILA as a potential prognostic biomarker for ESCC patients.

Main Methods:

• Analysis of NKILA expression in ESCC tissues and cell lines.
• Correlation analysis between NKILA expression and clinicopathological features.
• In vitro and in vivo loss- and gain-of-function assays to assess NKILA's effects on cell proliferation, migration, tumor growth, and metastasis.
• Investigation of NKILA's impact on the NF-κB signaling pathway.

Main Results:

• NKILA expression was significantly downregulated in ESCC tissues and cells.
• Low NKILA expression correlated with larger tumor size, advanced TNM stage, and poorer patient survival.
• NKILA inhibited ESCC cell proliferation and migration in vitro, and suppressed tumor growth and lung metastasis in vivo.
• NKILA abrogated NF-κB signaling by inhibiting IκBα phosphorylation, p65 nuclear translocation, and NF-κB target gene expression.

Conclusions:

• NKILA acts as a tumor suppressor in ESCC by inhibiting the NF-κB signaling pathway.
• NKILA downregulation is associated with malignant progression and poor prognosis in ESCC.
• NKILA holds potential as a valuable prognostic marker for ESCC.